Outcomes for Patients with Residual Stage II/III Breast Cancer Following Neoadjuvant Chemotherapy (AFT-01)

Area of Science:

• Oncology
• Breast Cancer Research
• Clinical Outcomes

Background:

• Pathologic complete response (pCR) after neoadjuvant chemotherapy is linked to improved survival in breast cancer.
• Outcomes for patients not achieving pCR, stratified by receptor status, require further investigation.
• Understanding survival and recurrence patterns in residual Stage II/III breast cancer is crucial for treatment optimization.

Purpose of the Study:

• To evaluate survival and distant recurrence rates in patients with residual Stage II/III breast cancer.
• To analyze these outcomes based on specific receptor statuses (ER, PR, Her2neu).
• To identify patient subgroups with poorer prognoses following neoadjuvant chemotherapy.

Main Methods:

• A cohort of 11,366 patients with Stage II-III breast cancer was analyzed from the National Cancer Database (2006-2007).
• Patients with residual pathologic Stage II/III disease were identified and categorized by receptor status (ER/PR+/Her2neu-, ER/PR-/Her2neu-, Her2neu+).
• Kaplan-Meier curves and multivariable Cox regression were used to assess 5-year survival and distant recurrence, calculating hazard ratios.

Main Results:

• Estrogen receptor (ER) and progesterone receptor (PR) negative/Her2neu negative (ER and PR-/Her2neu-) residual cancers showed the poorest 5-year overall survival (52%) and distant recurrence-free survival (57%).
• Compared to ER or PR+/Her2neu- and Her2neu+ subtypes, ER and PR-/Her2neu- disease had significantly higher risks of distant recurrence (HR 2.25) and mortality (HR 3.19).
• The study identified distinct survival and recurrence patterns based on receptor status in patients with residual disease after neoadjuvant chemotherapy.

Conclusions:

• Patients with residual ER and PR-/Her2neu- breast cancer exhibit a significantly elevated risk of distant recurrence and mortality.
• These findings suggest that intensified adjuvant therapy strategies should be considered for this high-risk cohort.
• Further clinical trials are warranted to explore novel treatment approaches for patients with residual ER and PR-/Her2neu- breast cancer.